1 / 1
Custom Deslorelin CAS: 57773-65-6 Manufacturer, Manufacturers
Product Description
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.
Therapeutic Areas
Veterinary Application (Approved)
- Animal reproductive management: Widely used for reproductive suppression or estrus cycle regulation in animals such as dogs, cats, and horses, such as suppressing estrus in female dogs and controlling sexual behavior in male horses.
- Treatment of animal diseases: Used to treat diseases related to sex hormones, such as prostate disease and hyperadrenocorticism in dogs.
Human Medical Applications (Research/Development)
- Reproductive endocrine disorders: It has been studied for the treatment of hormone-dependent diseases such as precocious puberty, endometriosis, and uterine fibroids.
- Prostate cancer and breast cancer: As a GnRH agonist, it can theoretically be used as adjuvant therapy for hormone-sensitive tumors, but other analogues (such as leuprorelin and goserelin) are more commonly used.
- Assisted reproductive technology: Pituitary downregulation in controlled ovarian stimulation (COS) cycles has been explored, but the current mainstream clinical drugs are other GnRH analogs.
Outlook & Development
Veterinary Status
- Approved Veterinary Applications: Highly effective for animal reproductive management including estrus cycle regulation and behavioral control in species like dogs, cats, and horses.
- Disease Management: Established clinical application in managing canine prostate disease and hyperadrenocorticism.
Human Medicine Potential
- Endocrine & Oncology Research: Ongoing exploration for precocious puberty, endometriosis, uterine fibroids, and hormone-sensitive oncology therapies.
- Market Competition: While explored in controlled ovarian stimulation (COS), mainstream clinical adoptance remains dominated by established GnRH analogues.
Conclusion
Deslorelin, as a GnRH agonist, is currently primarily valued in the veterinary field, particularly as a mature tool for companion animal reproductive control. In human medicine, its development has stalled due to market competition and patent issues. Future breakthroughs may depend on novel delivery systems or targeted therapy innovations, but it is unlikely to change the existing treatment landscape in the short term.
Frequently Asked Questions (FAQ)
1. What is Deslorelin and how does it work?
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog that is 30–150 times more potent than natural GnRH. It acts as a GnRH agonist, initially triggering a brief release of gonadotropins before causing pituitary desensitization and receptor downregulation to suppress sex steroid hormone production.
2. What are the approved veterinary applications for Deslorelin?
Deslorelin is widely approved for animal reproductive management, such as controlling estrus cycles in female dogs and sexual behavior in male horses. It is also used to treat sex hormone-related diseases like prostate disease and hyperadrenocorticism in dogs.
3. Is Deslorelin commonly used in human medicine?
No, human medical applications for Deslorelin remain largely in the research and development stage. Its development stalled primarily due to patent issues and strong market competition from other GnRH analogs like leuprorelin and goserelin.
4. What human health conditions have been studied with Deslorelin?
It has been researched for managing hormone-dependent reproductive endocrine disorders (precocious puberty, endometriosis, uterine fibroids), hormone-sensitive cancers (prostate and breast cancer), and pituitary downregulation in assisted reproductive technology.
5. What is the future outlook for Deslorelin in clinical applications?
While Deslorelin remains a mature tool for companion animal reproductive control, future human medical advancements will likely depend on novel drug delivery systems or targeted therapies, though rapid short-term changes in the market landscape are unlikely.
